Three Specialists Who Don't Talk to Each Other

A 28-year-old woman sits in a cardiologist's office. Her heart rate rises from 72 beats per minute lying down to 118 beats per minute within three minutes of standing. She is lightheaded, nauseated, and exhausted by noon every day. The cardiologist diagnoses postural orthostatic tachycardia syndrome. He prescribes a beta-blocker, compression stockings, and increased salt and fluid intake. He does not ask about her joints.

The same woman sits in an allergist's office. She develops hives after eating, flushing after exercise, and episodes of abdominal cramping and diarrhea that do not correlate with any identifiable food allergy. Serum tryptase is normal between episodes but elevated during a flare. The allergist diagnoses mast cell activation syndrome. She is prescribed antihistamines, a mast cell stabilizer, and advised to identify triggers. The allergist does not ask about her heart rate.

The same woman sits in a geneticist's office, after a two-year wait for the appointment. She has hypermobile joints, chronic pain, subluxations of her shoulders and fingers, skin that bruises easily, and a family history of similar problems. She meets the 2017 criteria for hypermobile Ehlers-Danlos syndrome. The geneticist documents the diagnosis and refers her back to her primary care physician for management. The geneticist does not connect the EDS to the POTS or the MCAS, because genetics does not manage either condition.

Three specialists. Three diagnoses. One person. No one in the system sees all three.

The Co-occurrence

The co-occurrence of hypermobile EDS, POTS, and mast cell activation syndrome is documented at rates that strongly suggest shared underlying biology rather than coincidence.

Among people with hEDS, approximately 58% to 80% also have POTS, depending on the study and the diagnostic criteria applied. Among people with POTS, approximately 31% meet the full 2017 diagnostic criteria for hEDS, and an additional 24% have generalized joint hypermobility that falls short of the full criteria. Among women with hEDS or hypermobility spectrum disorder, 32% meet diagnostic criteria for MCAS, and 25% carry all three diagnoses simultaneously.

People with hEDS are 29.7 times more likely to be diagnosed with POTS than the general population. This is not a modest association. It is a signal large enough to suggest that the conditions share a biological pathway, or that one condition causes or predisposes to the others.

The triad clusters overwhelmingly in women, typically presenting in the late teens to thirties. A 2024 study from Houston Methodist identified the cluster as a significant contributor to severe gastrointestinal symptoms, including intractable nausea, gastroparesis, and chronic constipation, predominantly in women aged 20 to 40.

The Proposed Mechanisms

The mechanisms linking the three conditions are proposed and plausible. They are not yet experimentally confirmed.

The leading hypothesis for POTS in hEDS involves vascular connective tissue. If the collagen in blood vessel walls is abnormally lax, the veins may dilate excessively when a person stands. Blood pools in the legs and abdomen. The heart rate increases to compensate for the reduced venous return. The result is tachycardia on standing, lightheadedness, fatigue, and the constellation of symptoms that define POTS. Small fiber neuropathy, which is more prevalent in EDS than in the general population, may compound the problem by impairing the autonomic nerves that regulate vascular tone.

The link between connective tissue laxity and mast cell activation is less well characterized. One hypothesis is that mast cells embedded in abnormal connective tissue are mechanically destabilized, leading to inappropriate degranulation and release of histamine, tryptase, prostaglandins, and other inflammatory mediators. Another is that the autonomic dysfunction associated with POTS independently triggers mast cell activation through aberrant sympathetic signaling. A third is that connective tissue abnormalities and mast cell dysfunction share a genetic basis that has not yet been identified.

The uncertainty about mechanisms does not diminish the clinical reality. A person who has all three conditions experiences a specific pattern of symptoms: heart racing and lightheadedness on standing, flushing and hives from unpredictable triggers, joint pain and subluxations, gastrointestinal dysfunction (nausea, bloating, constipation, diarrhea), fatigue that worsens upright and improves lying down, and cognitive difficulty during symptomatic episodes. The symptom burden is multiplicative, not additive. Each condition worsens the others.

Why the System Separates Them

Cardiology manages POTS. The diagnostic workup involves a tilt-table test or active standing test, an electrocardiogram, and sometimes autonomic function testing. Treatment is beta-blockers, ivabradine, midodrine, fludrocortisone, salt loading, compression garments, and exercise programs. Cardiology training covers POTS as a form of dysautonomia. It does not cover connective tissue disorders or mast cell biology.

Immunology or allergy manages MCAS. The diagnostic workup involves measuring serum tryptase (often normal between episodes), urinary prostaglandin and histamine metabolites, and sometimes bone marrow biopsy to exclude systemic mastocytosis. Treatment is H1 and H2 antihistamines, mast cell stabilizers (cromolyn sodium, ketotifen), leukotriene inhibitors, and trigger avoidance. Immunology training covers mast cell disorders. It does not cover autonomic physiology or joint hypermobility.

Genetics or rheumatology manages hEDS. The diagnostic evaluation involves clinical assessment of joint hypermobility (Beighton score), evaluation of systemic features (skin involvement, family history, musculoskeletal complications), and exclusion of other connective tissue disorders through genetic testing for the types of EDS that have identified genes. Treatment is physical therapy, joint protection strategies, pain management, and referral to other specialists for associated conditions. Genetics training covers connective tissue disorders. It does not cover cardiology or immunology.

The referral structure sends each symptom to the specialist trained to see it. No specialist is trained to see the triad as a triad. The person with all three conditions receives three independent workups, three independent treatment plans, and three independent follow-up schedules. No one coordinates the care. No one asks whether the beta-blocker prescribed for POTS interacts with the antihistamine prescribed for MCAS. No one evaluates whether the exercise program prescribed for POTS exacerbates the joint instability managed by the EDS treatment plan.

What the Person Sees

The person with the triad is the only one in the room who sees all three. She knows that her POTS symptoms flare when her MCAS is active, because histamine causes vasodilation, which worsens blood pooling. She knows that her joints sublux more frequently when she is deconditioned from the POTS-related exercise intolerance. She knows that the stress of managing chronic pain from EDS triggers autonomic and mast cell responses.

She brings this information to each specialist appointment. The cardiologist listens politely and writes "reports mast cell symptoms" in the chart. The allergist listens and writes "reports POTS." The geneticist writes "has POTS and MCAS" and moves on. No one integrates the information. No one changes their treatment plan based on what the other two specialists are doing.

The person becomes her own case manager. She reads research papers. She joins online communities where other people with the triad share medication combinations, dietary strategies, and lists of providers who understand the overlap. She brings printed studies to appointments. Some clinicians appreciate this. Others dismiss it.

What Data Changes

The triad is invisible in the current clinical data infrastructure for the same reason it is invisible in the clinical referral structure: the data from each specialist is siloed in a separate part of the medical record.

The POTS data lives in the cardiology notes. The MCAS data lives in the allergy or immunology notes. The EDS data lives in the genetics notes. No algorithm in any existing electronic health record system flags the co-occurrence. No registry tracks all three conditions in the same person. No research database enables cross-condition analysis of symptom trajectories, treatment responses, and outcome patterns across the triad.

When thousands of people contribute structured data about all three conditions simultaneously, the pattern becomes computationally visible. The data can answer questions that no single-disease study can: Does POTS symptom severity predict MCAS flare frequency? Do specific antihistamine combinations improve POTS symptoms? Does physical therapy for EDS reduce autonomic dysfunction? Is there a subgroup within the triad population that shares a distinct genetic signature?

These questions are unanswerable in disease-specific databases because the data from each condition never occupies the same analytical space. A multi-condition data infrastructure designed to capture the full symptom profile of the person, not the symptom profile of each diagnosis in isolation, is the tool that resolves what the referral system cannot see.

The Emerging Research

The triad is increasingly recognized in the research literature. A 2024 study from Houston Methodist explicitly described the cluster as a disease entity warranting integrated clinical evaluation. Multiple academic centers now have multidisciplinary clinics that evaluate POTS, MCAS, and EDS together rather than in separate departments.

The connection between hypermobility and Long COVID has expanded the research interest further. A 2024 study published in Frontiers in Neurology documented shared pathophysiology between Long COVID and hypermobility spectrum disorders, including autonomic dysfunction, mast cell activation, and small fiber neuropathy. The post-COVID dysautonomia population, which is large enough to attract research funding and clinical attention, is generating data that the pre-existing EDS/POTS/MCAS community has been collecting informally for years.

The irony is precise. The rare disease community identified the triad through lived experience decades before the research community validated it. The data existed in community forums, Facebook groups, and Reddit threads. It was dismissed as anecdotal because it was unstructured. The structured research that validates what affected communities have known for 20 years is now arriving, driven partly by a pandemic that made dysautonomia visible to clinicians who had previously never encountered it.

The triad is three diagnoses. It is one problem. The clinical system that separates them into three departments will eventually be redesigned by the data that shows they belong together. The question is how many years of fragmented care the current generation endures before the redesign arrives.